CY1118430T1 - Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου - Google Patents
Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορουInfo
- Publication number
- CY1118430T1 CY1118430T1 CY20161101220T CY161101220T CY1118430T1 CY 1118430 T1 CY1118430 T1 CY 1118430T1 CY 20161101220 T CY20161101220 T CY 20161101220T CY 161101220 T CY161101220 T CY 161101220T CY 1118430 T1 CY1118430 T1 CY 1118430T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compound
- treatment
- subunits
- administered
- therapeutic factors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Obesity (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Περιγράφονται μέθοδοι για την τροποποίηση των επιπέδων φωσφόρου στον ορό όπου χορηγούνται ασβεστιομιμητικοί παράγοντες σε ένα υποκείμενο το οποίο έχει την ανάγκη αυτών. Σε μία εφαρμογή η ένωση είναι cinacalcet και σε άλλες εφαρμογές η ένωση αποτελείται από μία γειτονική αλληλουχία υπομονάδων Χ1, - Χ2 - Χ3 - Χ4 – X5 - Χ6 - Χ7, όπου η υπομονάδα Χ1 περιλαμβάνει ένα τμήμα το οποίο περιέχει θειόλη και την κατανομή του φορτίου στις υπομονάδες Χ2 - Χ7. Η ένωση όταν χορηγείται σε επιλεγμένες χρονικές στιγμές σε έναν ασθενή ο οποίος υποβάλλεται σε διαπίδυση μειώνει τα επίπεδα φωσφόρου στον ορό σχετικά προς τα επίπεδα προ της δόσης και επιτυγχάνει ένα παρατεταμένο μειωμένο επίπεδο για μία χρονική περίοδο μετά την χορήγηση.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161494874P | 2011-06-08 | 2011-06-08 | |
| PCT/US2012/041759 WO2012170955A1 (en) | 2011-06-08 | 2012-06-08 | Therapeutic agents for regulating serum phosphorus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1118430T1 true CY1118430T1 (el) | 2017-06-28 |
Family
ID=46321485
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20161101220T CY1118430T1 (el) | 2011-06-08 | 2016-11-24 | Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8969299B2 (el) |
| EP (1) | EP2717896B1 (el) |
| JP (1) | JP5982473B2 (el) |
| KR (1) | KR102057508B1 (el) |
| CN (1) | CN103857405B (el) |
| AU (1) | AU2012267470C1 (el) |
| BR (1) | BR112013031539A2 (el) |
| CA (1) | CA2837445C (el) |
| CY (1) | CY1118430T1 (el) |
| DK (1) | DK2717896T3 (el) |
| ES (1) | ES2607986T3 (el) |
| HR (1) | HRP20161566T1 (el) |
| HU (1) | HUE032087T2 (el) |
| LT (1) | LT2717896T (el) |
| MX (1) | MX337613B (el) |
| PL (1) | PL2717896T3 (el) |
| PT (1) | PT2717896T (el) |
| RS (1) | RS55503B1 (el) |
| RU (1) | RU2612912C2 (el) |
| SG (1) | SG195290A1 (el) |
| SI (1) | SI2717896T1 (el) |
| SM (1) | SMT201700081B (el) |
| WO (1) | WO2012170955A1 (el) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8999932B2 (en) | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
| PE20210413A1 (es) * | 2013-06-28 | 2021-03-04 | Amgen Inc | Formulacion liquida estable que comprende etelcalcetida (amg416), un agente tamponante y agente de tonicidad |
| RU2686086C1 (ru) * | 2018-05-17 | 2019-04-24 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом |
| AU2020399030A1 (en) * | 2019-12-09 | 2022-06-23 | Beijing Tuo Jie Biopharmaceutical Co. Ltd. | Calcium-sensing receptor agonist compound and application thereof |
| KR20230066044A (ko) * | 2020-09-10 | 2023-05-12 | 샨시 마이콧 테크놀로지 컴퍼니 리미티드 | 이중특이적 융합 폴리펩타이드 화합물 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| AU9131091A (en) | 1990-11-07 | 1992-06-11 | Scripps Research Institute, The | Peptides that inhibit platelet binding of adhesion molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| WO1995006056A1 (en) | 1993-08-20 | 1995-03-02 | University Of Medicine & Dentistry Of New Jersey | Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same |
| CA2145214A1 (en) | 1995-02-28 | 1996-08-29 | Rick E. Preddie | Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans |
| US5688489A (en) | 1995-09-15 | 1997-11-18 | Resolution Pharmaceuticals, Inc. | Non-receptor mediated imaging agents |
| US5895368A (en) * | 1996-09-23 | 1999-04-20 | Medisystems Technology Corporation | Blood set priming method and apparatus |
| US6165977A (en) | 1996-10-18 | 2000-12-26 | Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific activators of protein kinase C methods and compositions |
| US6258774B1 (en) | 1998-03-19 | 2001-07-10 | University Of Medicine And Dentistry Of New Jersey | Carrier for in vivo delivery of a therapeutic agent |
| JP2000336099A (ja) | 1999-05-27 | 2000-12-05 | Sekisui Chem Co Ltd | ペプチド及びｃ型肝炎抗体検出用試薬 |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| IL153378A0 (en) | 2000-07-18 | 2003-07-06 | Bone Care Internat Inc | STABILIZED 1alpha-HYDROXY VITAMIN D |
| US20080249016A1 (en) | 2000-09-18 | 2008-10-09 | Sanos Bioscience A/S | Use of GLP-2 in a combination treatment for bone-related disorders |
| US20020168354A1 (en) | 2000-11-10 | 2002-11-14 | Daria Mochly-Rosen | psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia |
| AU2002226061B2 (en) | 2001-01-18 | 2007-08-02 | The Board Of Trustees Of The Leland Stanford Junior University | Peptides for activation and inhibition of delta PKC |
| WO2002062396A2 (en) | 2001-02-08 | 2002-08-15 | University Of Medicine And Dentistry Of New Jersey | Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates |
| US20030036627A1 (en) | 2001-02-16 | 2003-02-20 | Montelaro Ronald C. | Virus derived antimicrobial peptides |
| CN1255428C (zh) | 2001-02-23 | 2006-05-10 | 波利弗尔有限公司 | 具有抗微生物活性的模板固定化肽模拟物 |
| JP2005287302A (ja) | 2002-04-03 | 2005-10-20 | Haruhiko Fujiwara | ポリペプチドの架橋方法 |
| US20040018976A1 (en) | 2002-05-14 | 2004-01-29 | Feder John N. | Polynucleotide encoding novel human G-protein coupled receptors, and splice variants thereof |
| WO2004093821A2 (en) | 2003-04-22 | 2004-11-04 | Hawaii Biotech, Inc. | Treatment of anthrax infection using inhibitors of lethal factor protease activity |
| WO2005049647A2 (en) | 2003-11-05 | 2005-06-02 | Pevion Biotech Ltd. | Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens |
| CA2549052A1 (en) | 2003-12-11 | 2005-06-30 | The Board Of Trustees Of The Leland Stanford Junior University | Isozyme-specific antagonists of protein kinase c |
| WO2005072340A2 (en) | 2004-01-27 | 2005-08-11 | Compugen Ltd. | Novel polynucleotides encoding polypeptides and methods using same |
| US7265092B2 (en) | 2004-09-30 | 2007-09-04 | Kai Pharmaceuticals, Inc. | Pharmaceutical formulation |
| ITME20040015A1 (it) * | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| EP1937064A4 (en) | 2005-08-30 | 2009-09-16 | Acologix Inc | REGULATION OF MINERALS AND SKELETAL METABOLISM |
| WO2007038172A2 (en) | 2005-09-23 | 2007-04-05 | Nitto Denko Corporation | Guanidinium carriers |
| KR101552843B1 (ko) | 2006-11-16 | 2015-09-14 | 카이 파마슈티컬즈 | 부갑상선 기능항진증 및 고칼슘혈증 장애의 치료를 위한 폴리양이온성 칼슘 조절제 펩타이드 |
| CN101675067B (zh) | 2007-01-19 | 2013-09-11 | 凯制药公司 | 肽组合物的修饰以提高稳定性和递送效率 |
| NZ584048A (en) | 2007-10-02 | 2012-08-31 | Marina Biotech Inc | Lipopeptides for delivery of nucleic acids |
| US8716437B2 (en) | 2007-12-07 | 2014-05-06 | Steven A. Goldstein | Identification of toxin ligands |
| US8999932B2 (en) * | 2009-07-29 | 2015-04-07 | Kai Pharmaceuticals, Inc. | Therapeutic agents for reducing parathyroid hormone levels |
-
2012
- 2012-06-08 PL PL12728907T patent/PL2717896T3/pl unknown
- 2012-06-08 BR BR112013031539A patent/BR112013031539A2/pt not_active Application Discontinuation
- 2012-06-08 KR KR1020137034736A patent/KR102057508B1/ko active IP Right Grant
- 2012-06-08 US US13/492,778 patent/US8969299B2/en active Active
- 2012-06-08 CA CA2837445A patent/CA2837445C/en active Active
- 2012-06-08 RU RU2013157928A patent/RU2612912C2/ru active IP Right Revival
- 2012-06-08 WO PCT/US2012/041759 patent/WO2012170955A1/en active Application Filing
- 2012-06-08 SI SI201230784A patent/SI2717896T1/sl unknown
- 2012-06-08 PT PT127289072T patent/PT2717896T/pt unknown
- 2012-06-08 AU AU2012267470A patent/AU2012267470C1/en active Active
- 2012-06-08 SG SG2013089594A patent/SG195290A1/en unknown
- 2012-06-08 DK DK12728907.2T patent/DK2717896T3/en active
- 2012-06-08 HU HUE12728907A patent/HUE032087T2/en unknown
- 2012-06-08 RS RS20161021A patent/RS55503B1/sr unknown
- 2012-06-08 JP JP2014514910A patent/JP5982473B2/ja active Active
- 2012-06-08 CN CN201280038112.5A patent/CN103857405B/zh active Active
- 2012-06-08 EP EP12728907.2A patent/EP2717896B1/en active Active
- 2012-06-08 ES ES12728907.2T patent/ES2607986T3/es active Active
- 2012-06-08 MX MX2013014249A patent/MX337613B/es active IP Right Grant
- 2012-06-08 LT LTEP12728907.2T patent/LT2717896T/lt unknown
-
2016
- 2016-11-23 HR HRP20161566TT patent/HRP20161566T1/hr unknown
- 2016-11-24 CY CY20161101220T patent/CY1118430T1/el unknown
-
2017
- 2017-02-06 SM SM201700081T patent/SMT201700081B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5982473B2 (ja) | 2016-08-31 |
| AU2012267470B2 (en) | 2017-06-15 |
| HUE032087T2 (en) | 2017-08-28 |
| BR112013031539A2 (pt) | 2019-07-30 |
| SI2717896T1 (sl) | 2017-04-26 |
| ES2607986T3 (es) | 2017-04-05 |
| AU2012267470C1 (en) | 2017-09-21 |
| KR102057508B1 (ko) | 2019-12-19 |
| PT2717896T (pt) | 2016-12-23 |
| RS55503B1 (sr) | 2017-05-31 |
| US20130150301A1 (en) | 2013-06-13 |
| EP2717896B1 (en) | 2016-08-24 |
| RU2612912C2 (ru) | 2017-03-13 |
| PL2717896T3 (pl) | 2017-05-31 |
| EP2717896A1 (en) | 2014-04-16 |
| CN103857405A (zh) | 2014-06-11 |
| CA2837445A1 (en) | 2012-12-13 |
| CN103857405B (zh) | 2015-12-02 |
| JP2014522414A (ja) | 2014-09-04 |
| MX337613B (es) | 2016-03-10 |
| LT2717896T (lt) | 2017-02-27 |
| HRP20161566T1 (hr) | 2017-02-24 |
| KR20140035456A (ko) | 2014-03-21 |
| RU2013157928A (ru) | 2015-07-20 |
| SMT201700081B (it) | 2017-03-08 |
| CA2837445C (en) | 2022-10-04 |
| MX2013014249A (es) | 2014-01-24 |
| DK2717896T3 (en) | 2016-12-19 |
| WO2012170955A1 (en) | 2012-12-13 |
| SG195290A1 (en) | 2013-12-30 |
| US8969299B2 (en) | 2015-03-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118430T1 (el) | Θεραπευτικοι παραγοντες για τη ρυθμιση του φωσφορου εντος του ορου | |
| CY1123255T1 (el) | Σχημα δοσολογιας για εναν αγωνιστη υποδοχεα s1p | |
| CY1122687T1 (el) | Συνθεσεις και μεθοδοι για την τροποποιηση της smn2 συναρμογης σε ενα υποκειμενο | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| CY1122428T1 (el) | Θεραπευτικη αγωγη της παιδιατρικης οξειας λεμφοβλαστικης λευχαιμιας με διειδικα αντισωματα εναντι cd3xcd19 | |
| CY1123571T1 (el) | Βουπροπιονη για τη ρυθμιση των φαρμακευτικων επιπεδων δεξτρομεθορφανης στο πλασμα | |
| CY1121041T1 (el) | Μεθοδοι αγωγης παιδιατρικων ασθενων με τη χρηση δεξμεδετομιδινης | |
| CY1123258T1 (el) | Μεθοδος θεραπειας για τον καρκινο | |
| CY1122624T1 (el) | Θεραπεια συνδυασμου του καρκινου | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| EA201590693A1 (ru) | Ингибиторы gdf-8 | |
| EA202090338A1 (ru) | Функционально-модифицированные олигонуклеотиды и их субъединицы | |
| CY1117964T1 (el) | Αντιψυχωτικη ενεσιμη συνθεση μακρας διαρκειας δρασης τεχνικος τομεας | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| EA201591825A1 (ru) | Антагонизм миостатина у субъектов - людей | |
| CO2017012454A2 (es) | Secuencias de uricasa adecuadas para el tratamiento de hiperuricemia | |
| CY1122403T1 (el) | Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης | |
| CY1123583T1 (el) | Ανοσογονος συνθεση για χρηση στη θεραπεια | |
| EA201491702A1 (ru) | Оптимизированные терапевтические агенты для подкожного введения | |
| CY1122746T1 (el) | Ιατρικες αγωγες με βαση την αναμορελινη | |
| CY1117831T1 (el) | Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη του καρκινου του μαστου | |
| CL2018001434A1 (es) | Terapia cíclica con 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona | |
| EA201390417A1 (ru) | Антидиабетические твердые фармацевтические композиции | |
| WO2011006084A3 (en) | Vaccines with oncofetal antigen/ilrp-loaded autologous dendritic cells and uses thereof | |
| CY1112203T1 (el) | Καινοτομικες θεραπευτικες χρησεις της αδρενεργικης αλφουζοσινης |